DrugPatentWatch Database Preview

Details for Patent: 7,682,634

« Back to Dashboard

Which drugs does patent 7,682,634 protect, and when does it expire?

Patent 7,682,634 protects EMBEDA and is included in one NDA.

This patent has thirty-five patent family members in twenty-one countries.

Summary for Patent: 7,682,634

Title:	Pharmaceutical compositions
Abstract:	Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
Inventor(s):	Matthews; Frank (Edison, NJ), Boehm; Garth (Westfield, NJ), Tang; Lijuan (Flemington, NJ), Liang; Alfred (Edison, NJ)
Assignee:	Alpharma Pharmaceuticals, LLC (Bridgewater, NJ)
Application Number:	12/399,923
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 7,682,634

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		RX	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009		RX	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009		RX	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-004	Aug 13, 2009		RX	Yes	Yes			Y

Non-Orange Book US Patents Family Members for Patent 7,682,634

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,846,104	Pharmaceutical compositions for the deterrence and/or prevention of abuse
8,877,247	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
7,682,633	Pharmaceutical composition
8,158,156	Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist

International Patents Family Members for US Patent 7,682,634

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	552829
Australia	2007261451
Australia	2013257508
Australia	2016238844